Valevia has been awarded a prestigious Biomedical Catalyst grant from the Technology Strategy Board. The Biomedical Catalyst is an integrated translational funding programme that can support innovative ideas that demonstrate the potential to provide significant positive healthcare and economic impact, and awards are given to high quality projects proposed by UK companies after a strict evaluation process. With the grant, Valevia’s lead anti-bacterial compound will be moved forward in preclinical development for Clostridium difficile.
Previous data showed positive activity of VAL301 against a wide range of strains of Clostridium difficile including hypervirulent strains. The initial focus on Clostridium difficile infections will be followed by investigation in other uses of the compound. VAL301 is being developed in collaboration with Avexa Ltd, a biotechnology company located in Melbourne, Australia. The considerable interest in the antibiotics market and in particular Clostridium difficile treatment market has been confirmed by a number of transactions in the field.